RUA Life Sciences (RUA) AI Stock Analysis

RUA Life Sciences

(LSE:RUA)

Select Model

Rating:56Neutral

Price Target:GBX 31.00▲(8.77% Upside)

Action:reiterated

Date:09/26/26

The score is held back primarily by weak financial performance quality—ongoing operating losses and continued negative operating/free cash flow—despite improving results and a low-leverage balance sheet. Technical trends are supportive (price above major moving averages and positive MACD), but valuation remains challenged given negative earnings and no dividend data.

Positive Factors

Specialized biomaterials platformThe company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.

Negative Factors

Operating losses persistOperating profitability has not yet been established, so strong gross margin is not currently translating into sustainable earnings after operating costs. Continued EBIT losses could restrict internal funding, delay shareholder returns, and leave results sensitive to the timing of customer-program progress.

RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: GBP 17.69M
Dividend Yield: ―
Average Volume (3M): 139.12K
Price to Earnings (P/E): -123.9
Beta (1Y): 0.09
Revenue Growth: ―
EPS Growth: ―
Country: UK
Employees: 59
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

RUA Life Sciences Business Overview & Revenue Model

Company Description

RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's ope...

How the Company Makes Money

RUA Life Sciences generates revenue primarily by supplying biomaterials and related services to medical device companies and other healthcare manufacturers. Key revenue streams include: (1) Biomaterials sales: selling proprietary or specialized medic...

RUA Life Sciences Financial Statement Overview

Summary

Revenue growth and strong gross margin (~69% in 2026) are positives, and the balance sheet is conservatively levered (debt-to-equity ~0.11). However, operating profitability is not yet established (negative EBIT margin ~-18.5%) and cash generation remains weak with negative operating and free cash flow in 2026, which materially constrains the score.

Income Statement

44Neutral

Balance Sheet

78Positive

Cash Flow

34Negative

Financial statement breakdown
Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	4.46M	4.11M	2.19M	2.18M	1.63M	1.53M
Gross Profit	3.06M	3.17M	1.72M	1.43M	1.04M	980.00K
EBITDA	-383.33K	401.00K	-1.57M	-1.95M	-2.04M	-1.28M
Net Income	-145.33K	1,000	-1.44M	-2.00M	-2.07M	-1.45M
Balance Sheet
Total Assets	9.12M	9.26M	8.17M	5.66M	7.63M	10.15M
Cash, Cash Equivalents and Short-Term Investments	3.25M	3.57M	3.93M	1.48M	2.96M	6.29M
Total Debt	794.00K	1.03M	389.00K	475.00K	344.00K	410.00K
Total Liabilities	1.89M	1.86M	987.00K	980.00K	1.04M	1.65M
Stockholders Equity	7.14M	7.30M	7.18M	4.68M	6.58M	8.51M
Cash Flow
Free Cash Flow	-298.00K	-281.00K	-1.38M	-1.62M	-3.27M	-2.04M
Operating Cash Flow	-137.00K	-219.00K	-1.33M	-1.17M	-2.36M	-1.42M
Investing Cash Flow	-59.00K	70.00K	-85.00K	-449.00K	-904.00K	-943.00K
Financing Cash Flow	-459.00K	-196.00K	3.89M	132.00K	-66.00K	6.68M

RUA Life Sciences Technical Analysis

Technical Analysis SentimentPositive

Last Price28.50

Price Trends

50DMA28.02Positive

100DMA25.28Positive

200DMA20.85Positive

Market Momentum

MACD-0.16Positive

RSI54.57Neutral

STOCH60.94Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 28.50 is above the 20-day moving average (MA) of 28.18, above the 50-day MA of 28.02, and above the 200-day MA of 20.85, indicating a bullish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 60.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.

RUA Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:RUA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:RUA	56Neutral	GBP 17.69M	-123.91	-2.03%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 15.65M	-0.89	-1044.57%	―	65.60%	74.84%
GB:IHC	48Neutral	GBP 15.47M	-25.37	-3.85%	―	0.88%	94.67%
GB:SUN	44Neutral	GBP 3.73M	-4.00	-15.47%	―	-3.68%	20.00%
GB:OPTI	41Neutral	GBP 5.99M	-1.40	-77.85%	―	11.90%	-2864.29%
GB:CREO	38Underperform	GBP 51.09M	-2.51	-38.29%	―	―	―

* Healthcare Sector Average

Performance Comparison

GB:RUA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:RUA	Rua Life Sciences Plc	28.50	16.50	137.50%
GB:CREO	Creo Medical	11.38	0.13	1.11%
GB:GDR	Genedrive plc	0.97	0.01	1.25%
GB:IHC	Inspiration Healthcare	17.25	-3.00	-14.81%
GB:OPTI	OptiBiotix Health	5.80	-2.20	-27.50%
GB:SUN	Surgical Innovations Group Plc	0.40	-0.18	-31.03%

RUA Life Sciences Corporate Events

Business Operations and StrategyFinancial Disclosures

RUA Life Sciences Narrows Losses as Core Manufacturing Turns Profitable and Spin-Out Strategy Takes Shape

Positive

Jun 30, 2026

RUA Life Sciences reported interim results for the six months to 31 March 2026 showing a sharp narrowing of losses as it consolidates its shift toward profitable contract manufacturing and biomaterials licensing. Group revenue rose 6.1% to £2.75...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026

RUA Life Sciences AI Stock Analysis